| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 119 | 2024 | 2500 | 12.020 |
Why?
|
| Stroke Volume | 28 | 2023 | 578 | 4.960 |
Why?
|
| Myocarditis | 12 | 2024 | 194 | 3.090 |
Why?
|
| Cardiology | 22 | 2024 | 574 | 2.930 |
Why?
|
| Cardiovascular Diseases | 22 | 2024 | 2307 | 2.120 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 12 | 2019 | 262 | 2.120 |
Why?
|
| Atrial Fibrillation | 8 | 2023 | 752 | 2.070 |
Why?
|
| Obesity | 15 | 2024 | 2958 | 1.860 |
Why?
|
| Natriuretic Peptide, Brain | 11 | 2021 | 340 | 1.680 |
Why?
|
| Hospitalization | 21 | 2021 | 2202 | 1.660 |
Why?
|
| Ventricular Function, Left | 10 | 2017 | 580 | 1.590 |
Why?
|
| Angiotensin Receptor Antagonists | 6 | 2016 | 151 | 1.460 |
Why?
|
| Cardiomyopathies | 7 | 2024 | 560 | 1.450 |
Why?
|
| Comorbidity | 12 | 2024 | 2439 | 1.390 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2024 | 1435 | 1.290 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 4 | 2018 | 33 | 1.260 |
Why?
|
| Ventricular Dysfunction, Left | 8 | 2024 | 414 | 1.250 |
Why?
|
| American Heart Association | 20 | 2024 | 349 | 1.200 |
Why?
|
| Humans | 196 | 2024 | 271884 | 1.050 |
Why?
|
| Catheter Ablation | 2 | 2023 | 575 | 1.040 |
Why?
|
| Amyloidosis | 3 | 2024 | 185 | 1.030 |
Why?
|
| Adrenergic beta-Antagonists | 8 | 2019 | 330 | 1.020 |
Why?
|
| Spironolactone | 3 | 2015 | 26 | 0.990 |
Why?
|
| Neoplasms | 19 | 2024 | 15915 | 0.980 |
Why?
|
| Cardiotoxicity | 9 | 2024 | 161 | 0.960 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2020 | 771 | 0.930 |
Why?
|
| Glucagon-Like Peptides | 1 | 2024 | 31 | 0.930 |
Why?
|
| Acute Coronary Syndrome | 4 | 2022 | 256 | 0.900 |
Why?
|
| Antiphospholipid Syndrome | 1 | 2023 | 40 | 0.850 |
Why?
|
| United States | 54 | 2024 | 16050 | 0.820 |
Why?
|
| Ambulatory Care | 8 | 2018 | 604 | 0.820 |
Why?
|
| Cardiomyopathy, Hypertrophic | 5 | 2021 | 177 | 0.810 |
Why?
|
| Renin-Angiotensin System | 5 | 2019 | 112 | 0.800 |
Why?
|
| Atherosclerosis | 7 | 2023 | 957 | 0.800 |
Why?
|
| Registries | 9 | 2023 | 2250 | 0.790 |
Why?
|
| Guideline Adherence | 4 | 2021 | 649 | 0.770 |
Why?
|
| Percutaneous Coronary Intervention | 4 | 2020 | 369 | 0.740 |
Why?
|
| Aged | 81 | 2024 | 73471 | 0.740 |
Why?
|
| Cardiovascular System | 4 | 2023 | 151 | 0.730 |
Why?
|
| Cardiac Imaging Techniques | 4 | 2021 | 49 | 0.730 |
Why?
|
| Coronavirus | 1 | 2020 | 38 | 0.720 |
Why?
|
| Risk Factors | 43 | 2024 | 18045 | 0.710 |
Why?
|
| Hypoglycemic Agents | 4 | 2024 | 620 | 0.670 |
Why?
|
| Medical Oncology | 4 | 2024 | 1463 | 0.670 |
Why?
|
| Body Mass Index | 9 | 2020 | 2258 | 0.670 |
Why?
|
| Coronary Artery Disease | 6 | 2022 | 946 | 0.650 |
Why?
|
| Risk Assessment | 13 | 2022 | 6883 | 0.650 |
Why?
|
| Quality of Health Care | 3 | 2021 | 632 | 0.640 |
Why?
|
| Patient Readmission | 7 | 2020 | 592 | 0.630 |
Why?
|
| Hospitals, Veterans | 4 | 2020 | 380 | 0.630 |
Why?
|
| Kidney Diseases | 3 | 2019 | 732 | 0.630 |
Why?
|
| Diuretics | 8 | 2016 | 181 | 0.630 |
Why?
|
| Male | 100 | 2024 | 128957 | 0.620 |
Why?
|
| Biomarkers | 19 | 2023 | 5112 | 0.610 |
Why?
|
| Heart | 6 | 2023 | 1214 | 0.600 |
Why?
|
| Phosphodiesterase 5 Inhibitors | 5 | 2015 | 27 | 0.580 |
Why?
|
| Female | 98 | 2024 | 149143 | 0.570 |
Why?
|
| Iron | 1 | 2020 | 382 | 0.570 |
Why?
|
| Hypertension, Pulmonary | 2 | 2020 | 472 | 0.570 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2024 | 1841 | 0.570 |
Why?
|
| Thrombosis | 1 | 2023 | 755 | 0.550 |
Why?
|
| Myocardial Infarction | 6 | 2020 | 1304 | 0.550 |
Why?
|
| Inpatients | 2 | 2021 | 695 | 0.540 |
Why?
|
| Diabetes Mellitus | 6 | 2019 | 1076 | 0.540 |
Why?
|
| Coronary Disease | 3 | 2022 | 783 | 0.540 |
Why?
|
| Middle Aged | 75 | 2024 | 90395 | 0.540 |
Why?
|
| Practice Patterns, Nurses' | 1 | 2016 | 13 | 0.540 |
Why?
|
| Heart Diseases | 4 | 2024 | 739 | 0.510 |
Why?
|
| Heart-Assist Devices | 6 | 2023 | 1056 | 0.490 |
Why?
|
| Retrospective Studies | 43 | 2024 | 39780 | 0.480 |
Why?
|
| Tetrazoles | 4 | 2011 | 102 | 0.470 |
Why?
|
| Valine | 4 | 2011 | 184 | 0.470 |
Why?
|
| Obesity, Morbid | 1 | 2017 | 238 | 0.460 |
Why?
|
| Cardiovascular Agents | 4 | 2016 | 117 | 0.450 |
Why?
|
| Drug Monitoring | 1 | 2016 | 356 | 0.450 |
Why?
|
| Quality of Life | 5 | 2021 | 4749 | 0.450 |
Why?
|
| Randomized Controlled Trials as Topic | 7 | 2009 | 2679 | 0.450 |
Why?
|
| Cytokines | 11 | 2023 | 2840 | 0.440 |
Why?
|
| Practice Guidelines as Topic | 7 | 2021 | 2429 | 0.440 |
Why?
|
| Hyponatremia | 1 | 2014 | 87 | 0.420 |
Why?
|
| Receptors, Cytokine | 4 | 2011 | 183 | 0.420 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 633 | 0.420 |
Why?
|
| Thromboembolism | 2 | 2023 | 153 | 0.420 |
Why?
|
| Sodium | 1 | 2014 | 355 | 0.420 |
Why?
|
| Peptide Fragments | 5 | 2021 | 1327 | 0.410 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 709 | 0.410 |
Why?
|
| Vasodilator Agents | 4 | 2015 | 238 | 0.410 |
Why?
|
| Cohort Studies | 18 | 2021 | 9491 | 0.410 |
Why?
|
| Veterans | 5 | 2016 | 1779 | 0.400 |
Why?
|
| Myositis | 2 | 2024 | 88 | 0.390 |
Why?
|
| Outpatients | 2 | 2014 | 469 | 0.390 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 1737 | 0.390 |
Why?
|
| Prognosis | 23 | 2023 | 22537 | 0.380 |
Why?
|
| Double-Blind Method | 13 | 2016 | 2619 | 0.370 |
Why?
|
| Platelet Aggregation Inhibitors | 3 | 2019 | 352 | 0.370 |
Why?
|
| Exercise Tolerance | 5 | 2015 | 114 | 0.360 |
Why?
|
| Prevalence | 12 | 2024 | 3426 | 0.360 |
Why?
|
| Coronary Artery Bypass | 3 | 2015 | 568 | 0.360 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2019 | 852 | 0.360 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2020 | 1335 | 0.350 |
Why?
|
| Tumor Necrosis Factor-alpha | 9 | 2011 | 1613 | 0.350 |
Why?
|
| Incidence | 13 | 2021 | 5861 | 0.350 |
Why?
|
| Acute Disease | 7 | 2024 | 2514 | 0.350 |
Why?
|
| Patient Care Management | 2 | 2020 | 94 | 0.350 |
Why?
|
| Leptin | 1 | 2011 | 312 | 0.340 |
Why?
|
| Follow-Up Studies | 19 | 2019 | 15267 | 0.340 |
Why?
|
| Research Report | 5 | 2022 | 144 | 0.340 |
Why?
|
| Cardiotonic Agents | 3 | 2016 | 163 | 0.340 |
Why?
|
| Molecular Targeted Therapy | 1 | 2020 | 2400 | 0.330 |
Why?
|
| Societies, Medical | 3 | 2019 | 1349 | 0.320 |
Why?
|
| Overweight | 2 | 2024 | 489 | 0.320 |
Why?
|
| Quality Indicators, Health Care | 2 | 2016 | 364 | 0.310 |
Why?
|
| Treatment Outcome | 34 | 2021 | 33863 | 0.310 |
Why?
|
| Piperazines | 5 | 2015 | 2152 | 0.310 |
Why?
|
| Sulfones | 3 | 2013 | 149 | 0.300 |
Why?
|
| Myocardial Ischemia | 3 | 2008 | 434 | 0.300 |
Why?
|
| Hyperlipidemias | 2 | 2022 | 237 | 0.300 |
Why?
|
| Blood Pressure | 8 | 2021 | 1603 | 0.300 |
Why?
|
| Receptors, Tumor Necrosis Factor | 6 | 2003 | 214 | 0.290 |
Why?
|
| Echocardiography | 3 | 2024 | 1241 | 0.280 |
Why?
|
| Glomerular Filtration Rate | 7 | 2020 | 604 | 0.280 |
Why?
|
| Digoxin | 2 | 2021 | 55 | 0.280 |
Why?
|
| Metformin | 1 | 2010 | 395 | 0.270 |
Why?
|
| Severity of Illness Index | 10 | 2021 | 4399 | 0.270 |
Why?
|
| Electrocardiography | 4 | 2021 | 1196 | 0.270 |
Why?
|
| Thiazolidinediones | 1 | 2007 | 154 | 0.270 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 1 | 2007 | 203 | 0.270 |
Why?
|
| Heart Rate | 4 | 2021 | 761 | 0.270 |
Why?
|
| Nurse Practitioners | 2 | 2018 | 61 | 0.270 |
Why?
|
| Hemodynamics | 6 | 2021 | 973 | 0.270 |
Why?
|
| Physician Assistants | 2 | 2018 | 78 | 0.260 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 31042 | 0.260 |
Why?
|
| Renal Dialysis | 4 | 2020 | 931 | 0.260 |
Why?
|
| Chronic Disease | 5 | 2023 | 1849 | 0.260 |
Why?
|
| Antineoplastic Agents | 3 | 2023 | 14653 | 0.260 |
Why?
|
| Depressive Disorder | 1 | 2009 | 566 | 0.260 |
Why?
|
| Hospital Mortality | 6 | 2021 | 1317 | 0.250 |
Why?
|
| Ventricular Dysfunction | 1 | 2005 | 34 | 0.250 |
Why?
|
| Time Factors | 15 | 2020 | 13130 | 0.250 |
Why?
|
| Sex Factors | 8 | 2020 | 2206 | 0.240 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 2 | 2023 | 82 | 0.240 |
Why?
|
| Mortality | 4 | 2024 | 354 | 0.240 |
Why?
|
| Stroke | 2 | 2017 | 1094 | 0.240 |
Why?
|
| Survival Rate | 8 | 2019 | 12533 | 0.240 |
Why?
|
| Anti-Arrhythmia Agents | 3 | 2023 | 238 | 0.230 |
Why?
|
| Research Design | 4 | 2012 | 1580 | 0.230 |
Why?
|
| Captopril | 1 | 2003 | 37 | 0.230 |
Why?
|
| Kidney Transplantation | 3 | 2019 | 789 | 0.230 |
Why?
|
| Pericarditis | 1 | 2024 | 62 | 0.220 |
Why?
|
| Circulating MicroRNA | 1 | 2023 | 25 | 0.220 |
Why?
|
| Anxiety Disorders | 1 | 2009 | 725 | 0.220 |
Why?
|
| Troponin T | 2 | 2016 | 263 | 0.220 |
Why?
|
| Hypertension | 6 | 2019 | 1624 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2007 | 544 | 0.220 |
Why?
|
| Cardiologists | 1 | 2023 | 33 | 0.220 |
Why?
|
| Dopamine | 2 | 2016 | 341 | 0.220 |
Why?
|
| Weight Loss | 3 | 2023 | 639 | 0.220 |
Why?
|
| Survival Analysis | 8 | 2018 | 9325 | 0.220 |
Why?
|
| Assisted Circulation | 1 | 2023 | 39 | 0.220 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 118 | 0.220 |
Why?
|
| Vitamin K | 1 | 2023 | 55 | 0.210 |
Why?
|
| Age Factors | 8 | 2018 | 5520 | 0.210 |
Why?
|
| Patient Selection | 5 | 2020 | 2043 | 0.210 |
Why?
|
| Drug Administration Schedule | 7 | 2012 | 3539 | 0.210 |
Why?
|
| Clinical Trials as Topic | 5 | 2023 | 3853 | 0.210 |
Why?
|
| Myocardium | 3 | 2020 | 1251 | 0.210 |
Why?
|
| Cystatin C | 4 | 2016 | 58 | 0.210 |
Why?
|
| Cardio-Renal Syndrome | 2 | 2012 | 8 | 0.210 |
Why?
|
| Heart Valve Prosthesis Implantation | 2 | 2021 | 487 | 0.210 |
Why?
|
| Evidence-Based Medicine | 7 | 2021 | 1059 | 0.210 |
Why?
|
| Heart Transplantation | 4 | 2023 | 904 | 0.210 |
Why?
|
| Inflammation | 2 | 2023 | 2533 | 0.200 |
Why?
|
| Vinca Alkaloids | 1 | 2021 | 9 | 0.200 |
Why?
|
| Adult | 21 | 2024 | 81857 | 0.200 |
Why?
|
| Endothelium, Vascular | 3 | 2015 | 898 | 0.200 |
Why?
|
| Bisoprolol | 1 | 2021 | 13 | 0.200 |
Why?
|
| Acute Kidney Injury | 2 | 2020 | 784 | 0.190 |
Why?
|
| Lung Transplantation | 2 | 2023 | 389 | 0.190 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2016 | 66 | 0.190 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2023 | 156 | 0.190 |
Why?
|
| Health Services Research | 1 | 2003 | 243 | 0.190 |
Why?
|
| Random Allocation | 1 | 2003 | 746 | 0.190 |
Why?
|
| Aortic Diseases | 1 | 2023 | 195 | 0.190 |
Why?
|
| Quinolines | 2 | 2001 | 403 | 0.190 |
Why?
|
| Adverse Drug Reaction Reporting Systems | 1 | 2021 | 100 | 0.190 |
Why?
|
| Heart Valves | 1 | 2021 | 62 | 0.190 |
Why?
|
| Consensus | 6 | 2023 | 1116 | 0.190 |
Why?
|
| Cerebrovascular Disorders | 2 | 2016 | 160 | 0.190 |
Why?
|
| Prosthesis Implantation | 2 | 2020 | 244 | 0.180 |
Why?
|
| Valsartan | 4 | 2011 | 32 | 0.180 |
Why?
|
| Weight Gain | 1 | 2023 | 474 | 0.180 |
Why?
|
| Glucosides | 1 | 2020 | 63 | 0.180 |
Why?
|
| Telemetry | 1 | 2020 | 41 | 0.180 |
Why?
|
| Kidney Failure, Chronic | 2 | 2018 | 960 | 0.180 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 329 | 0.180 |
Why?
|
| Practice Patterns, Physicians' | 3 | 2018 | 1322 | 0.180 |
Why?
|
| Veterans Health | 2 | 2019 | 179 | 0.180 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2020 | 85 | 0.180 |
Why?
|
| Benzhydryl Compounds | 1 | 2020 | 87 | 0.180 |
Why?
|
| Erythropoietin | 1 | 2021 | 219 | 0.170 |
Why?
|
| Diastole | 2 | 2014 | 190 | 0.170 |
Why?
|
| Proportional Hazards Models | 6 | 2014 | 5118 | 0.170 |
Why?
|
| Myasthenia Gravis | 1 | 2021 | 107 | 0.170 |
Why?
|
| Radiation, Ionizing | 1 | 2020 | 192 | 0.170 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2021 | 320 | 0.170 |
Why?
|
| Home Care Services | 1 | 2020 | 100 | 0.170 |
Why?
|
| Losartan | 2 | 2011 | 46 | 0.170 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2022 | 382 | 0.170 |
Why?
|
| General Practitioners | 1 | 2019 | 19 | 0.170 |
Why?
|
| Heart Valve Diseases | 1 | 2021 | 197 | 0.170 |
Why?
|
| Health Care Costs | 1 | 2024 | 699 | 0.170 |
Why?
|
| Metabolic Syndrome | 2 | 2016 | 374 | 0.170 |
Why?
|
| Anticoagulants | 2 | 2023 | 792 | 0.170 |
Why?
|
| Predictive Value of Tests | 8 | 2020 | 4998 | 0.160 |
Why?
|
| Antigens, CD19 | 1 | 2022 | 584 | 0.160 |
Why?
|
| Administration, Oral | 1 | 2023 | 1620 | 0.160 |
Why?
|
| Diagnosis, Computer-Assisted | 1 | 2020 | 169 | 0.160 |
Why?
|
| Interleukin-6 | 5 | 2011 | 1066 | 0.160 |
Why?
|
| Thinness | 1 | 2019 | 82 | 0.160 |
Why?
|
| Hemorrhage | 1 | 2023 | 747 | 0.150 |
Why?
|
| Wearable Electronic Devices | 1 | 2020 | 115 | 0.150 |
Why?
|
| Physicians | 2 | 2017 | 870 | 0.150 |
Why?
|
| Purinergic P2Y Receptor Antagonists | 1 | 2018 | 59 | 0.150 |
Why?
|
| Semantics | 1 | 2018 | 56 | 0.150 |
Why?
|
| Prospective Studies | 14 | 2021 | 13400 | 0.150 |
Why?
|
| Taxoids | 1 | 2021 | 1010 | 0.150 |
Why?
|
| Advisory Committees | 1 | 2019 | 209 | 0.150 |
Why?
|
| Disease Management | 2 | 2021 | 1111 | 0.150 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 177 | 0.150 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2022 | 629 | 0.150 |
Why?
|
| Procollagen | 2 | 2014 | 32 | 0.150 |
Why?
|
| Logistic Models | 5 | 2016 | 3469 | 0.150 |
Why?
|
| Cachexia | 1 | 2019 | 168 | 0.150 |
Why?
|
| ST Elevation Myocardial Infarction | 1 | 2020 | 142 | 0.140 |
Why?
|
| Population Surveillance | 1 | 2021 | 650 | 0.140 |
Why?
|
| Preventive Health Services | 1 | 2018 | 73 | 0.140 |
Why?
|
| Protein Precursors | 2 | 2021 | 252 | 0.140 |
Why?
|
| Kidney | 3 | 2016 | 2265 | 0.140 |
Why?
|
| Secondary Prevention | 1 | 2019 | 322 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 5104 | 0.140 |
Why?
|
| Ventricular Remodeling | 4 | 2012 | 192 | 0.140 |
Why?
|
| Urination | 1 | 2016 | 35 | 0.140 |
Why?
|
| Machine Learning | 1 | 2020 | 358 | 0.140 |
Why?
|
| Precision Medicine | 1 | 2024 | 1207 | 0.140 |
Why?
|
| Echocardiography, Doppler | 2 | 2014 | 188 | 0.130 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1136 | 0.130 |
Why?
|
| Aspirin | 2 | 2018 | 392 | 0.130 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 848 | 0.130 |
Why?
|
| Confidence Intervals | 4 | 2015 | 758 | 0.130 |
Why?
|
| Sulfonamides | 2 | 2015 | 1919 | 0.130 |
Why?
|
| Biopsy | 2 | 2021 | 3544 | 0.130 |
Why?
|
| Xanthine Oxidase | 1 | 2015 | 21 | 0.130 |
Why?
|
| Positron-Emission Tomography | 1 | 2024 | 2198 | 0.130 |
Why?
|
| Anemia | 1 | 2021 | 730 | 0.130 |
Why?
|
| Betacoronavirus | 1 | 2020 | 522 | 0.130 |
Why?
|
| Myocardial Contraction | 3 | 2015 | 306 | 0.130 |
Why?
|
| Cocaine | 1 | 2017 | 245 | 0.120 |
Why?
|
| Immunoglobulin G | 1 | 1999 | 1140 | 0.120 |
Why?
|
| Renin | 3 | 2012 | 103 | 0.120 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2016 | 226 | 0.120 |
Why?
|
| Patient Discharge | 4 | 2020 | 711 | 0.120 |
Why?
|
| Cause of Death | 2 | 2017 | 787 | 0.120 |
Why?
|
| Hyperuricemia | 1 | 2015 | 49 | 0.120 |
Why?
|
| ROC Curve | 2 | 2024 | 1248 | 0.120 |
Why?
|
| Football | 1 | 2014 | 32 | 0.120 |
Why?
|
| Pandemics | 2 | 2021 | 1606 | 0.120 |
Why?
|
| Thoracic Surgical Procedures | 1 | 2018 | 261 | 0.120 |
Why?
|
| Cocaine-Related Disorders | 1 | 2017 | 240 | 0.120 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2023 | 5566 | 0.120 |
Why?
|
| Radiation Injuries | 1 | 2022 | 1472 | 0.120 |
Why?
|
| Allopurinol | 1 | 2015 | 87 | 0.120 |
Why?
|
| Natriuretic Agents | 1 | 2013 | 33 | 0.110 |
Why?
|
| Anthropometry | 1 | 2014 | 264 | 0.110 |
Why?
|
| Sildenafil Citrate | 4 | 2015 | 57 | 0.110 |
Why?
|
| Brain Ischemia | 1 | 2016 | 316 | 0.110 |
Why?
|
| Collagen Type I | 1 | 2014 | 191 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 247 | 0.110 |
Why?
|
| Neoplasms, Second Primary | 1 | 2022 | 1388 | 0.110 |
Why?
|
| Diagnostic Imaging | 1 | 2021 | 1177 | 0.110 |
Why?
|
| Residence Characteristics | 1 | 2016 | 361 | 0.110 |
Why?
|
| Myocardial Revascularization | 1 | 2014 | 135 | 0.110 |
Why?
|
| Texas | 7 | 2021 | 6435 | 0.110 |
Why?
|
| Primary Prevention | 1 | 2015 | 243 | 0.110 |
Why?
|
| Natriuretic Peptides | 1 | 2012 | 7 | 0.110 |
Why?
|
| Ultrafiltration | 1 | 2012 | 26 | 0.110 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2009 | 678 | 0.110 |
Why?
|
| Heart Failure, Diastolic | 1 | 2012 | 10 | 0.110 |
Why?
|
| Sarcoma | 1 | 2023 | 1842 | 0.110 |
Why?
|
| Renal Insufficiency | 2 | 2006 | 318 | 0.110 |
Why?
|
| Global Health | 1 | 2018 | 691 | 0.110 |
Why?
|
| Drug Therapy, Combination | 4 | 2018 | 2366 | 0.100 |
Why?
|
| Peripheral Arterial Disease | 1 | 2016 | 271 | 0.100 |
Why?
|
| Continuity of Patient Care | 1 | 2015 | 223 | 0.100 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2017 | 604 | 0.100 |
Why?
|
| Diagnostic Techniques, Cardiovascular | 1 | 2012 | 23 | 0.100 |
Why?
|
| Gastrointestinal Hemorrhage | 1 | 2015 | 349 | 0.100 |
Why?
|
| Purines | 4 | 2015 | 275 | 0.100 |
Why?
|
| Propanolamines | 1 | 2011 | 49 | 0.100 |
Why?
|
| Odds Ratio | 4 | 2016 | 2335 | 0.100 |
Why?
|
| Sex Distribution | 3 | 2015 | 502 | 0.100 |
Why?
|
| Animals | 8 | 2023 | 62807 | 0.100 |
Why?
|
| Carbazoles | 1 | 2011 | 92 | 0.100 |
Why?
|
| Shock, Cardiogenic | 1 | 2014 | 239 | 0.100 |
Why?
|
| Sensitivity and Specificity | 3 | 2016 | 5195 | 0.100 |
Why?
|
| Alcohol Drinking | 1 | 2015 | 600 | 0.100 |
Why?
|
| Reference Values | 2 | 2018 | 1155 | 0.100 |
Why?
|
| Furosemide | 1 | 2011 | 43 | 0.090 |
Why?
|
| Receptors, Interleukin-6 | 2 | 2001 | 67 | 0.090 |
Why?
|
| Sodium Potassium Chloride Symporter Inhibitors | 1 | 2011 | 32 | 0.090 |
Why?
|
| Calcinosis | 1 | 2014 | 432 | 0.090 |
Why?
|
| C-Reactive Protein | 2 | 2014 | 567 | 0.090 |
Why?
|
| Clinical Competence | 1 | 2019 | 1327 | 0.090 |
Why?
|
| Multimodal Imaging | 1 | 2015 | 553 | 0.090 |
Why?
|
| Troponin I | 1 | 2011 | 131 | 0.090 |
Why?
|
| Multicenter Studies as Topic | 2 | 2023 | 566 | 0.090 |
Why?
|
| Blood Sedimentation | 1 | 2010 | 38 | 0.090 |
Why?
|
| Decision Support Techniques | 3 | 2020 | 605 | 0.090 |
Why?
|
| Risk Adjustment | 2 | 2020 | 77 | 0.090 |
Why?
|
| MicroRNAs | 1 | 2023 | 2912 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1950 | 0.090 |
Why?
|
| Models, Cardiovascular | 1 | 2011 | 190 | 0.090 |
Why?
|
| Biphenyl Compounds | 1 | 2011 | 192 | 0.090 |
Why?
|
| Coronary Vessels | 1 | 2014 | 643 | 0.090 |
Why?
|
| Adrenergic alpha-1 Receptor Antagonists | 1 | 2009 | 27 | 0.080 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 2009 | 75 | 0.080 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2014 | 6270 | 0.080 |
Why?
|
| Lung Neoplasms | 2 | 2023 | 12012 | 0.080 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 16241 | 0.080 |
Why?
|
| Infusions, Intravenous | 4 | 2012 | 1441 | 0.080 |
Why?
|
| Chemokines | 1 | 2010 | 296 | 0.080 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 2168 | 0.080 |
Why?
|
| Multivariate Analysis | 4 | 2016 | 4352 | 0.080 |
Why?
|
| Drug Evaluation | 2 | 2008 | 435 | 0.080 |
Why?
|
| Quality Improvement | 1 | 2016 | 918 | 0.080 |
Why?
|
| Death, Sudden, Cardiac | 2 | 2020 | 252 | 0.080 |
Why?
|
| Peptides | 1 | 2014 | 1528 | 0.080 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 222 | 0.080 |
Why?
|
| Calcium | 1 | 2014 | 1594 | 0.080 |
Why?
|
| Pyrazines | 2 | 2001 | 513 | 0.080 |
Why?
|
| Collagen | 1 | 2011 | 739 | 0.080 |
Why?
|
| Benzimidazoles | 1 | 2011 | 442 | 0.080 |
Why?
|
| Endpoint Determination | 2 | 2015 | 183 | 0.080 |
Why?
|
| Hypothermia | 1 | 2008 | 67 | 0.080 |
Why?
|
| Fumarates | 1 | 2007 | 29 | 0.080 |
Why?
|
| Cultural Diversity | 1 | 2008 | 80 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2009 | 316 | 0.070 |
Why?
|
| Oxygen Consumption | 3 | 2013 | 423 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2024 | 6236 | 0.070 |
Why?
|
| Amides | 1 | 2007 | 119 | 0.070 |
Why?
|
| Seasons | 1 | 2008 | 337 | 0.070 |
Why?
|
| Regression Analysis | 1 | 2010 | 1588 | 0.070 |
Why?
|
| Postoperative Complications | 2 | 2020 | 5690 | 0.070 |
Why?
|
| Esophageal Neoplasms | 1 | 2020 | 3240 | 0.070 |
Why?
|
| Risk Reduction Behavior | 2 | 2019 | 223 | 0.070 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2009 | 906 | 0.070 |
Why?
|
| Databases, Factual | 2 | 2011 | 2287 | 0.070 |
Why?
|
| Heart Function Tests | 1 | 2005 | 76 | 0.070 |
Why?
|
| Drug Utilization | 1 | 2007 | 189 | 0.070 |
Why?
|
| Oxidative Stress | 3 | 2020 | 1158 | 0.070 |
Why?
|
| Algorithms | 4 | 2020 | 3923 | 0.060 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2024 | 6986 | 0.060 |
Why?
|
| APACHE | 1 | 2005 | 95 | 0.060 |
Why?
|
| Mammary Arteries | 1 | 2005 | 47 | 0.060 |
Why?
|
| Creatinine | 3 | 2012 | 546 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2012 | 802 | 0.060 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2005 | 121 | 0.060 |
Why?
|
| Utilization Review | 1 | 2004 | 54 | 0.060 |
Why?
|
| Walking | 2 | 2013 | 274 | 0.060 |
Why?
|
| Receptors, IgG | 1 | 2024 | 116 | 0.060 |
Why?
|
| Medicare | 2 | 2020 | 934 | 0.060 |
Why?
|
| Prostatic Neoplasms | 1 | 2021 | 5996 | 0.060 |
Why?
|
| Recovery of Function | 2 | 2021 | 691 | 0.060 |
Why?
|
| Troponin | 1 | 2023 | 91 | 0.060 |
Why?
|
| Survivorship | 1 | 2024 | 117 | 0.060 |
Why?
|
| Tissue Inhibitor of Metalloproteinases | 1 | 2002 | 37 | 0.050 |
Why?
|
| Sampling Studies | 1 | 2003 | 171 | 0.050 |
Why?
|
| Anxiety | 1 | 2010 | 1230 | 0.050 |
Why?
|
| Health Expenditures | 1 | 2024 | 201 | 0.050 |
Why?
|
| Exercise Test | 2 | 2015 | 315 | 0.050 |
Why?
|
| Disease Progression | 2 | 2012 | 6909 | 0.050 |
Why?
|
| Sample Size | 1 | 2003 | 215 | 0.050 |
Why?
|
| Heart Block | 1 | 2022 | 47 | 0.050 |
Why?
|
| Matrix Metalloproteinases | 1 | 2002 | 139 | 0.050 |
Why?
|
| Selection Bias | 1 | 2001 | 48 | 0.050 |
Why?
|
| Ribose | 1 | 2021 | 33 | 0.050 |
Why?
|
| Adenosine Diphosphate | 1 | 2021 | 102 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type II | 1 | 2001 | 29 | 0.050 |
Why?
|
| Androstenes | 1 | 2021 | 44 | 0.050 |
Why?
|
| Primary Health Care | 2 | 2018 | 843 | 0.050 |
Why?
|
| Cost of Illness | 1 | 2024 | 505 | 0.050 |
Why?
|
| New York | 1 | 2021 | 104 | 0.050 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 2001 | 75 | 0.050 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2023 | 257 | 0.050 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 163 | 0.050 |
Why?
|
| Exercise Therapy | 1 | 2023 | 292 | 0.050 |
Why?
|
| Expert Testimony | 1 | 2021 | 85 | 0.050 |
Why?
|
| Feedback | 1 | 2021 | 227 | 0.040 |
Why?
|
| Organs at Risk | 1 | 2023 | 560 | 0.040 |
Why?
|
| Health Behavior | 1 | 2005 | 602 | 0.040 |
Why?
|
| Cloud Computing | 1 | 2020 | 15 | 0.040 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2021 | 177 | 0.040 |
Why?
|
| Single-Cell Analysis | 1 | 2024 | 546 | 0.040 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2023 | 744 | 0.040 |
Why?
|
| Smartphone | 1 | 2020 | 45 | 0.040 |
Why?
|
| Depression | 1 | 2010 | 1736 | 0.040 |
Why?
|
| Demography | 1 | 2001 | 435 | 0.040 |
Why?
|
| Patient Care Team | 2 | 2015 | 830 | 0.040 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2008 | 1163 | 0.040 |
Why?
|
| Renal Elimination | 1 | 2019 | 12 | 0.040 |
Why?
|
| Etanercept | 1 | 1999 | 69 | 0.040 |
Why?
|
| Dietary Approaches To Stop Hypertension | 1 | 2019 | 8 | 0.040 |
Why?
|
| Age Distribution | 1 | 2001 | 730 | 0.040 |
Why?
|
| Aorta | 1 | 2023 | 683 | 0.040 |
Why?
|
| Diet, Mediterranean | 1 | 2019 | 14 | 0.040 |
Why?
|
| Surveys and Questionnaires | 3 | 2019 | 5928 | 0.040 |
Why?
|
| Anti-Obesity Agents | 1 | 2019 | 33 | 0.040 |
Why?
|
| Neurotransmitter Agents | 3 | 2008 | 174 | 0.040 |
Why?
|
| Aftercare | 1 | 2020 | 255 | 0.040 |
Why?
|
| Micronutrients | 1 | 2019 | 76 | 0.040 |
Why?
|
| Observational Studies as Topic | 1 | 2019 | 148 | 0.040 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 545 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 663 | 0.040 |
Why?
|
| Hematopoiesis | 1 | 2022 | 608 | 0.040 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2022 | 506 | 0.040 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2001 | 1534 | 0.040 |
Why?
|
| Dobutamine | 1 | 1998 | 60 | 0.040 |
Why?
|
| Health Status Disparities | 1 | 2021 | 320 | 0.040 |
Why?
|
| Artificial Intelligence | 1 | 2022 | 430 | 0.040 |
Why?
|
| Renal Replacement Therapy | 1 | 2019 | 152 | 0.040 |
Why?
|
| Urea | 1 | 2019 | 306 | 0.040 |
Why?
|
| Protective Factors | 1 | 2018 | 108 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2004 | 809 | 0.040 |
Why?
|
| Length of Stay | 1 | 2005 | 2015 | 0.040 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 1998 | 123 | 0.040 |
Why?
|
| Respiratory Insufficiency | 1 | 2021 | 347 | 0.040 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 327 | 0.040 |
Why?
|
| Sarcopenia | 1 | 2019 | 113 | 0.040 |
Why?
|
| Adrenergic beta-Agonists | 1 | 1998 | 141 | 0.040 |
Why?
|
| Hospital Costs | 1 | 2019 | 251 | 0.040 |
Why?
|
| Mice | 3 | 2023 | 36041 | 0.040 |
Why?
|
| Exercise | 1 | 2005 | 1214 | 0.040 |
Why?
|
| Dietary Proteins | 1 | 2019 | 256 | 0.040 |
Why?
|
| Bariatric Surgery | 1 | 2019 | 124 | 0.040 |
Why?
|
| Congresses as Topic | 1 | 2019 | 296 | 0.040 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 1313 | 0.040 |
Why?
|
| Ultrasonography | 2 | 2015 | 1943 | 0.040 |
Why?
|
| Internal Medicine | 1 | 2018 | 160 | 0.040 |
Why?
|
| Adolescent | 3 | 2023 | 32663 | 0.030 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2024 | 1657 | 0.030 |
Why?
|
| Equipment Design | 1 | 2020 | 1207 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2023 | 3131 | 0.030 |
Why?
|
| Counseling | 1 | 2019 | 385 | 0.030 |
Why?
|
| Forecasting | 1 | 2019 | 706 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2020 | 6210 | 0.030 |
Why?
|
| Antigens, CD | 1 | 2001 | 1436 | 0.030 |
Why?
|
| Malnutrition | 1 | 2019 | 226 | 0.030 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2005 | 1060 | 0.030 |
Why?
|
| Drug Prescriptions | 1 | 2018 | 321 | 0.030 |
Why?
|
| Alleles | 1 | 2022 | 2599 | 0.030 |
Why?
|
| India | 1 | 2016 | 313 | 0.030 |
Why?
|
| Hyperemia | 1 | 2015 | 37 | 0.030 |
Why?
|
| Alcohol Abstinence | 1 | 2015 | 17 | 0.030 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2015 | 33 | 0.030 |
Why?
|
| Transplantation Conditioning | 1 | 2024 | 2359 | 0.030 |
Why?
|
| Arterial Pressure | 1 | 2015 | 107 | 0.030 |
Why?
|
| Mitochondria | 1 | 2021 | 1313 | 0.030 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2014 | 64 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2015 | 74 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 534 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 108 | 0.030 |
Why?
|
| Vasodilation | 1 | 2015 | 218 | 0.030 |
Why?
|
| Magnetic Resonance Imaging, Cine | 1 | 2015 | 157 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 3072 | 0.030 |
Why?
|
| Developing Countries | 1 | 2016 | 340 | 0.030 |
Why?
|
| Urine | 1 | 2013 | 142 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 2452 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2021 | 4984 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2014 | 126 | 0.030 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2014 | 352 | 0.030 |
Why?
|
| Aldosterone | 1 | 2012 | 80 | 0.030 |
Why?
|
| DNA Damage | 1 | 2020 | 1989 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 2015 | 303 | 0.030 |
Why?
|
| Blood Urea Nitrogen | 1 | 2012 | 101 | 0.030 |
Why?
|
| Gout | 1 | 2015 | 147 | 0.030 |
Why?
|
| Hemofiltration | 1 | 2012 | 22 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2020 | 4003 | 0.020 |
Why?
|
| Uric Acid | 1 | 2012 | 121 | 0.020 |
Why?
|
| Coronary Angiography | 1 | 2015 | 568 | 0.020 |
Why?
|
| Models, Structural | 1 | 2011 | 95 | 0.020 |
Why?
|
| Young Adult | 2 | 2021 | 22108 | 0.020 |
Why?
|
| Rare Diseases | 1 | 2015 | 360 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2012 | 458 | 0.020 |
Why?
|
| Intention to Treat Analysis | 1 | 2011 | 124 | 0.020 |
Why?
|
| Systole | 1 | 2011 | 222 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2015 | 1402 | 0.020 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2012 | 188 | 0.020 |
Why?
|
| Cardiac Catheterization | 1 | 2015 | 693 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2016 | 2349 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 2011 | 596 | 0.020 |
Why?
|
| Pregnancy | 1 | 2023 | 8100 | 0.020 |
Why?
|
| Phenotype | 1 | 2021 | 6515 | 0.020 |
Why?
|
| Health Status | 1 | 2013 | 633 | 0.020 |
Why?
|
| Receptors, Adrenergic, alpha-1 | 1 | 2009 | 40 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2011 | 729 | 0.020 |
Why?
|
| Potassium | 1 | 2010 | 349 | 0.020 |
Why?
|
| Autonomic Agents | 1 | 2008 | 3 | 0.020 |
Why?
|
| Caregivers | 1 | 2015 | 734 | 0.020 |
Why?
|
| Selenoproteins | 1 | 2008 | 16 | 0.020 |
Why?
|
| Medical Records | 1 | 2009 | 447 | 0.020 |
Why?
|
| Ubiquinone | 1 | 2008 | 33 | 0.020 |
Why?
|
| Dyspnea | 1 | 2011 | 421 | 0.020 |
Why?
|
| Body Temperature | 1 | 2008 | 165 | 0.020 |
Why?
|
| Hypertrophy | 1 | 2008 | 165 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 1074 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 1950 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2008 | 232 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 1327 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2008 | 690 | 0.020 |
Why?
|
| Antioxidants | 1 | 2008 | 523 | 0.020 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2008 | 460 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2014 | 4507 | 0.010 |
Why?
|
| Fatigue | 1 | 2010 | 1280 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2015 | 7822 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2011 | 969 | 0.010 |
Why?
|
| Models, Statistical | 1 | 2009 | 1190 | 0.010 |
Why?
|
| Recurrence | 1 | 2011 | 4886 | 0.010 |
Why?
|
| Child | 1 | 2024 | 30492 | 0.010 |
Why?
|
| Diagnosis, Differential | 1 | 2012 | 4891 | 0.010 |
Why?
|
| Norepinephrine | 1 | 2003 | 285 | 0.010 |
Why?
|
| Mutation | 1 | 2022 | 15924 | 0.010 |
Why?
|
| Neovascularization, Pathologic | 1 | 2008 | 1599 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 995 | 0.010 |
Why?
|
| Coronary Circulation | 1 | 2001 | 257 | 0.010 |
Why?
|
| Linear Models | 1 | 2003 | 1100 | 0.010 |
Why?
|
| Enzyme Activation | 1 | 2002 | 1832 | 0.010 |
Why?
|
| Endothelin-1 | 1 | 1997 | 63 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2008 | 10259 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1998 | 543 | 0.010 |
Why?
|
| Mitral Valve | 1 | 1998 | 285 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2012 | 7929 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1998 | 1707 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 1999 | 4199 | 0.000 |
Why?
|